Phase IV study of Mu-Gard (Access Pharma) shows it is effective for Oral Mucositis
Top-line results from a Phase IV clinical trial evaluating Mu-Gard Mucoadhesive oral wound rinse, from Access Pharma, shows it was effective in controlling symptoms caused by Oral Mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck. Mu-Gard met the primary study endpoint, with patients receiving Mu-Gard experiencing a statistically significant reduction versus placebo in mouth and throat soreness.
In addition, fewer patients receiving Mu-Gard had ulcerative Oral Mucositis at the end of radiation therapy. Data was presented at the MASCC/ISOO International Symposium on Supportive Care.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins